Roche signs neurodegeneration pact with stealthy biotech, primarily focusing on ALS

Max Gelman

Senior Editor

Earlier this week, Roche partnered with a little-known biotech in a new neurological disease collaboration aiming to treat ALS and potentially other debilitating illnesses. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche signs neurodegeneration pact with stealthy biotech, primarily focusing on ALS

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA lifts hold on Entrada's Duchenne drug after two years

How AI can address ongoing challenges in the life sciences industry

Roche signs neu­rode­gen­er­a­tion pact with stealthy biotech, pri­mar­i­ly fo­cus­ing on ALS

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Roche signs neurodegeneration pact with stealthy biotech, primarily focusing on ALS